Clinical Trial Update: A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept clinical trial of LAD328 in adults with hidradenitis suppurativa has been announced, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• LAD328

Snippet

Sponsor: Almirall, S.A. | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: NOT_YET_RECRUITING